Human Fetal Fibroblasts(HFF)/Human Feeder Cells – Capstone Biotek Inc.
Novel feeder cells for cancer research and regenerative medicine
Capstone Biotek, Inc. (CBI) is a Taiwanese biotech company dedicated to the development of innovative solutions for the field of cancer research and regenerative medicine. CBI’s long term goal is to develop allogeneic therapeutic applications utilizing human fetal osteocytes, chondrocytes, and tenocytes to treat bone atrophy, knee disorders, and tendinopathy.
CBI’s Human Fetal Fibroblast (HFF) product is a xeno-free and FBS-free alternative to Mouse Embryonic Fibroblast (MEF) for culturing human stem cells such as human embryonic stem cells (hESC) and induced pluripotent stem cells (iPS).
To visit CBI’s official webpage, please click here.
CBI’s Human Fetal Fibroblast (CBI-HFF) is a first-in-class feeder cell product of human fetal origin. The cell line used to produce CBI-HFF has been well established and documented through a series of cGMP banking processes in Europe. The product cell bank is generated from a series of well-controlled cell production procedures to ensure quality and consistency. CBI-HFF is offered in both research/laboratory grade and clinical grade (GTP compliant, Research-Use-Only) to meet various experimental needs.
Applicable for culturing Epithelial Cells and hESC/iPS Cells
Mitomycin-C Treated and Ready-To-Use (RTU)
Strict Quality Control and Lot-to-Lot Consistency
Free of mycoplasma and microbial contamination
Xeno-Free/FBS-Free – no risk of animal pathogen contamination
Maintains the Pluripotency of hESC/iPS Cells
For more detailed information on the cell origin, properties, and related literature about CBI-HFF,
please refer to this official pamphlet from Capstone Biotek.
Please contact us for your any inquiries, questions and information requests.
Tokyo Future Style, Inc.